MAPS PBC

The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply. These are temporary codes assigned...

The for-profit arm of the legendary Multidisciplinary Association for Psychedelic Studies, MAPS Public Benefit Corporation (MAPS PBC), has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for MDMA (midomafetamine capsules) paired with...

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s clinical-stage private arm, published new data from its second multi-site, ethno-racially diverse Phase 3 clinical study of MDMA-assisted...

MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s clinical-stage private arm, published new data from its second multi-site, ethno-racially diverse Phase 3 clinical study of MDMA-assisted therapy for PTSD in Nature Medicine.  The randomized MAPP2 study gave participants a split...

The American Medical Association (AMA) published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies, as announced by its forwarders the MAPS Public Benefit Corporation and COMPASS Pathways (NASDAQ: CMPS)....

The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC and COMPASS Pathways (NASDAQ: CMPS). On March 3, the AMA published its Panel Actions summary which included the...

Zinger Keypoints: Long-term (over 1 year) follow-up reflects lasting improvements in symptom severity. Data confirms prior Phase 2 studies on MDMA-assisted therapy’s sustained effect on PTSD treatment. New Drug Application (NDA) to be submitted in Q3 2023 would be the last...

The legendary non-profit’s private arm, MAPS Public Benefit Corporation (MAPS PBC), announced that Frontiers in Psychiatry has published its first functional neuroimaging study evaluating how MDMA-assisted therapy works in people with PTSD. The MAPS study aimed at assessing how MDMA...

Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's Senate Health Committee. By prefiling the bill, Democratic sponsors Reps. Linda Rosenthal, Jo...

MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therapy for PTSD.  "The Phase 3 confirmatory results support...

MAPS Public Benefit Corporation (PBC) announced the final participant’s last Evaluation and Exit Planning therapeutic session was completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD.) A wholly-owned subsidiary...

Demand for specialized therapists capable of providing psychedelics-assisted treatments is expected to continue growing. At the same time, the number of people willing to get trained is expanding. In response, several leading psychedelic companies are developing their own training courses,...